Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

View:
Post by Ingiboy on Dec 13, 2022 7:53pm

What Next

From Stockwatch this afternoon:


Mr. Lee Buckler Reports:

"REPLICEL ANNOUNCES EXTENSION TO NON-BROKERED PRIVATE PLACEMENT

The TSX Venture Exchange has granted a two-week extension until Dec. 30, 2022, for completion of the company's non-brokered private placement.

The terms of the offering provide for the issuance of up to 10.5 million units at a price of 10 cents per unit for gross proceeds of up to $1.05-million. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each whole warrant entitles the holder thereof to purchase one additional share of the company at a price of 20 cents per share for a period of three years from closing of the offering. The offering is subject to the approval of the exchange. Insiders may participate in the offering."

O.K. a bit weird here. First this is from Lee Buckler who is no longer the CEO of the company. Secondly this is the second time they have extended the closing of the PP.  First it was Nov. 18th,  then it was Dec. 16th, now it is Dec. 30th.  
The first extension was due to "increased demand". If there was an increased demand from $800,000 from the first PP to $1,050,000 , what happened ?

 


REPLICEL ANNOUNCES EXTENSION TO NON-BROKERED PRIVATE PLACEMENT

The TSX Venture Exchange has granted a two-week extension until Dec. 30, 2022, for completion of the company's non-brokered private placement.

The terms of the offering provide for the issuance of up to 10.5 million units at a price of 10 cents per unit for gross proceeds of up to $1.05-million. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each whole warrant entitles the holder thereof to purchase one additional share of the company at a price of 20 cents per share for a period of three years from closing of the offering. The offering is subject to the approval of the exchange. Insiders may participate in the offering.

Fi

Comment by Ingiboy on Dec 14, 2022 1:31pm
It is pretty hard to sell a Private Placement at $.10 mind you with warrants when you can buy shares on the open market at $.09.  I was a bit surprised that the update didn't spark a little interest in Replicel. Unfortunatley there has been a bit to much "crying wolf" with this company for people to believe the hype. With this Shiseido Arbitration elephant in the room hanging ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities